NCT06321094View on ClinicalTrials.gov

Effect of Vericiguat on Endpoint Events in Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

December 1, 2025

Conditions
Acute Coronary SyndromeHeart Failure With Reduced Ejection Fraction
Interventions
DRUG

Vericiguat

Investigators divide our participants into two groups ;one group is required to take vericiguat,and the other isnot required to take vericiguat.Expect this,no intervention is used in the research.

Trial Locations (1)

Unknown

RECRUITING

the First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER